AbbVie Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.


Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending December 30, 2019 was $-8.17 Billion (a -0.66% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) increased by 4.42%
  • Annual Shareholders Equity (Total) for 2019 was $-8.17 Billion (a -3.24% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $-8.45 Billion (a -265.71% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2017 was $5.1 Billion (a 9.94% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of AbbVie Inc.

Most recent Shareholders Equity (Total)of ABBV including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of AbbVie Inc.

AbbVie Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-8,172.0 $-8,226.0 $-8,566.0 $-7,826.0 $-8,172.0
2018 $-8,446.0 $-2,921.0 $-3,375.0 $3,553.0 $-8,446.0
2017 $5,097.0 $6,687.0 $6,009.0 $4,998.0 $5,097.0
2016 $4,636.0 $6,469.0 $5,640.0 $4,643.0 $4,636.0
2015 $3,945.0 $4,863.0 $5,504.0 $1,377.0 $3,945.0
2014 $1,742.0 $4,645.0 $5,218.0 $4,697.0 $1,742.0
2013 $4,492.0 $3,577.0 $3,558.0 $2,957.0 $4,492.0
2012 $3,363.0 $15,668.84 $11,505.08 $12,050.77 $3,363.0
2011 $11,932.0 $0.0 $0.0 $0.0 $11,932.0
2010 $15,703.0 $15,703.0
2009 $0.0 $0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.